UPDATE 2-Side effects of Alnylam's gene-silencing drug raise concerns, shares slip
March 06, 2019 at 11:06 AM EST
Alnylam Pharmaceuticals Inc's late-stage trial data on its new gene silencing drug cast doubt on its safety, even as results revealed its effectiveness in treating a rare, painful disease.
